Patents by Inventor Michael A. Patane

Michael A. Patane has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7375125
    Abstract: Provided are MC4-R binding compounds of the formula XVII: wherein L2 is a linker group, and P1, P2, P3, P4, Z1, Z2, Z3, Z4, Z5, t, s, and R are as described in the specification. Methods of using the compounds to treat MC4-R associated disorders, such as disorders associated with weight loss, are also provided.
    Type: Grant
    Filed: June 16, 2003
    Date of Patent: May 20, 2008
    Assignee: Ore Pharmaceuticals, Inc.
    Inventors: Tricia J. Vos, Michael E. Solomon, Christopher F. Claiborne, Martin P. Maguire, Mingshi Dai, Michael Patane, Thomas H. Marsilje
  • Patent number: 7365070
    Abstract: This invention provides compounds and methods for treating melanocortin receptor associated disorders, such as weight loss disorders including cachexia resulting from cancer and other chronic illnesses. The compounds are represented by formula I: wherein X is oxygen or sulfur; G is G1 or G2: L1, L2, L3 and Q are linker groups, and Rings A, B and C, and R1-R14 are described in the specification. The compounds are antagonists of melanocortin receptors.
    Type: Grant
    Filed: December 4, 2003
    Date of Patent: April 29, 2008
    Assignee: Ore Pharmaceuticals Inc.
    Inventors: Tricia J. Vos, Michael Patane, Michael E. Solomon, Christopher Blackburn, Mihaela D. Danca
  • Publication number: 20080045530
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Application
    Filed: April 9, 2007
    Publication date: February 21, 2008
    Inventors: Trixi Brandl, Shawn Britt, Sylvain Cottens, Claus Ehrhardt, Jiping Fu, Subramanian Karur, Hongju Li, Peichao Lu, David Parker, Michael Patane, Branko Radetich, Prakash Raman, Stefan Randl, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic, Ritesh Tichkule, Yanyi Zhu
  • Publication number: 20070296098
    Abstract: The invention relates to liposomes, particularly, but not exclusively, to liposomes for introducing a molecule into a cell, and to processes for making and using liposomes.
    Type: Application
    Filed: December 15, 2005
    Publication date: December 27, 2007
    Applicant: Protech Research PTY LTD
    Inventor: Michael Patane
  • Publication number: 20070293498
    Abstract: This invention provides compounds and methods for treating melanocortin receptor associated disorders, such as weight loss disorders including cachexia resulting from cancer and other chronic illnesses. The compounds are represented by formula I: wherein X is oxygen or sulfur; G is G1 or G2: L1, L2, L3 and Q are linker groups, and Rings A, B and C, and R1-R14 are described in the specification. The compounds are antagonists of melanocortin receptors.
    Type: Application
    Filed: July 26, 2007
    Publication date: December 20, 2007
    Applicant: Gene Logic, Inc.
    Inventors: Tricia Vos, Michael Patane, Michael Solomon, Christopher Blackburn, Mihaela Danca
  • Publication number: 20070286842
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Application
    Filed: April 9, 2007
    Publication date: December 13, 2007
    Inventors: Trixi Brandl, Jiping Fu, Francois Lenoir, David Parker, Michael Patane, Branko Redetich, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic, Aregahegn Yifru, Rui Zheng
  • Publication number: 20070265281
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Application
    Filed: April 9, 2007
    Publication date: November 15, 2007
    Inventors: Sylvain Cottens, Claus Ehrhardt, Jiping Fu, David Parker, Michael Patane, Branko Radetich, Prakash Raman, Stefan Randl, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic, Dongpeng Wan
  • Publication number: 20070031957
    Abstract: A process for purifying a phosphodiesterase 1 (PDE-1) from a cell including heating an extract of a cell formed from a solution including at least on divalent cation, to increase the specific activity of PDE-1 in the extract.
    Type: Application
    Filed: October 5, 2006
    Publication date: February 8, 2007
    Applicant: Protech Research Pty Ltd
    Inventor: Michael Patane
  • Patent number: 7153862
    Abstract: The present invention relates to novel alkanoic acid derivatives thereof, their synthesis, and their use as ?v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors ?v?3 and/or ?v?5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth.
    Type: Grant
    Filed: July 10, 2003
    Date of Patent: December 26, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Ben C. Askew, Michael J. Breslin, Mark E. Duggan, John H. Hutchinson, Robert S. Meissner, James J. Perkins, Thomas G. Steele, Michael A. Patane
  • Patent number: 7045532
    Abstract: ACE-2 inhibitors for the treatment of body weight and related disorders are disclosed. ACE-2 inhibitors include peptides and small molecules. Examples of small molecule ACE-2 inhibitors include compounds of formula (I): Z-???(I) Wherein Z is a zinc coordinating moiety and ? is an amino-acid mimicking moiety, and pharmaceutically acceptabale salts thereof. Methods of using the inhibitors and pharmaceutical compositions containing the inhibitors to treat a body weight disorder, to decrease appetite, to increase muscle mass, to decrease body fat, to treat diabetes and to treat a state associated with altered lipid metabolism, are also described.
    Type: Grant
    Filed: October 31, 2001
    Date of Patent: May 16, 2006
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Susan L. Acton, Timothy D. Ocain, Alexandra E. Gould, Natalie A. Dales, Bing Guan, James A. Brown, Michael Patane, Vivek J. Kadambi, Michael Solomon, Alain Stricker-Krongrad
  • Publication number: 20060100194
    Abstract: The present invention provides novel compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Application
    Filed: October 3, 2005
    Publication date: May 11, 2006
    Inventors: Christopher Blackburn, Christopher Claiborne, Courtney Cullis, Natalie Dales, Michael Patane, Matthew Stirling, Omar Stradella, Gabriel Weatherhead
  • Publication number: 20060014263
    Abstract: A process for purifying a phosphodiesterase 1 (PDE-1) from a cell including heating an extract of a cell formed from a solution including at least on divalent cation, to increase the specific activity of PDE-1 in the extract.
    Type: Application
    Filed: June 6, 2005
    Publication date: January 19, 2006
    Inventor: Michael Patane
  • Patent number: 6982158
    Abstract: A process for purifying a phosphodiesterase 1 (PDE-1) from a cell including heating an extract of a cell formed from a solution including at least one divalent cation, to increase the specific activity of PDE-1 in the extract.
    Type: Grant
    Filed: December 11, 2003
    Date of Patent: January 3, 2006
    Assignee: Protech Research Pty Ltd
    Inventor: Michael Patane
  • Patent number: 6943156
    Abstract: The present invention relates to a novel dibenzoxazepine derivative, its synthesis, and its use as an ?v integrin receptor antagonist. More particularly, the compound of the present invention is an antagonist of the integrin receptors ?v?3 and ?v?5 and therefor useful for inhibiting bone resorption, treating and/or preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, artheroscietosis, inflammatory arthritis, cancer and metastatic tumor growth.
    Type: Grant
    Filed: October 19, 2001
    Date of Patent: September 13, 2005
    Assignee: Merck & Co., Inc
    Inventor: Michael A. Patane
  • Patent number: 6921821
    Abstract: This invention provides compounds that are antagonists of melanin concentrating hormone receptor-1 (MCH-R1). The compounds are represented by formula I: where m is zero or one, n is zero to two, Y is oxygen or —N(R9)—, R1, R2, R3, R4, R5, R9 and Ring A are defined in the specification. Coumarin and quinolone compounds where R1 and R2 together form a fused benzo ring are preferred. The invention also provides compounds of formula VI where the coumarin moiety is replaced by a quinazolinone ring. The compounds are useful for treating MCH-R1-related disorders, particularly overweight conditions including obesity.
    Type: Grant
    Filed: June 11, 2003
    Date of Patent: July 26, 2005
    Assignee: Abbott Laboratories
    Inventors: Christopher Blackburn, Su-Jen Lai, Jennifer L. Che, Martin P. Maguire, Michael A. Patane, Matthew J. LaMarche, Courtney A. Cullis, James Brown, Anil Vasudevan, Jennifer C. Freeman, Mathew M. Mulhern, John K. Lynch, Ju Gao, Dariusz Wodka, Andrew J. Souers, Rajesh Iyengar, Mary Katherin Verzal, Philip R. Kym
  • Publication number: 20050143372
    Abstract: The invention relates to compounds having the formula (I). Preferred compounds are antagonists of C—C chemokine receptor 8. The invention also relates to a method for treating a subjected having an inflammatory disorder or viral disorder comprising administering to a subject in need thereof an effective amount of a compound of the invention.
    Type: Application
    Filed: October 30, 2002
    Publication date: June 30, 2005
    Inventors: Shomir Ghosh, Michael Patane, Kenneth Carson, I-Cheng Chi, Qing Ye, Amy Elder, Tracy Jenkins
  • Publication number: 20040229332
    Abstract: A process for purifying a phosphodiesterase 1 (PDE-1) from a cell including heating an extract of a cell formed from a solution including at least one divalent cation, to increase the specific activity of PDE-1 in the extract.
    Type: Application
    Filed: December 11, 2003
    Publication date: November 18, 2004
    Inventor: Michael Patane
  • Patent number: 6784190
    Abstract: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors &agr;v&bgr;3, &agr;v&bgr;5, and/or &agr;v&bgr;6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.
    Type: Grant
    Filed: July 27, 2001
    Date of Patent: August 31, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Ben C. Askew, Paul J. Coleman, Mark E. Duggan, Wasyl Halczenko, George D. Hartman, Cecilia A. Hunt, John H. Hutchinson, Robert S. Meissner, Michael A. Patane, Garry R. Smith, Jiabing Wang
  • Publication number: 20040147746
    Abstract: This invention provides compounds and methods for treating melanocortin receptor associated disorders, such as weight loss disorders including cachexia resulting from cancer and other chronic illnesses.
    Type: Application
    Filed: December 4, 2003
    Publication date: July 29, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Tricia J. Vos, Michael Patane, Michael E. Solomon, Christopher Blackburn, Mihaela D. Danca
  • Publication number: 20040147028
    Abstract: A liposome for fusing with a yeast cell, the liposome characterised in that about 40-50 molar % of the liposome lipid bilayer is phosphatidyl choline (PC), about 10-20 molar % of the liposome lipid bilayer is a cationic amphiphile, about 10 molar % of the liposome lipid bilayer is a sterol and about 30 molar % of the liposome lipid bilayer is phosphatidyl ethanolamine (PE) and/or dioleoylphosphatidylethanolamine (DOPE).
    Type: Application
    Filed: December 11, 2003
    Publication date: July 29, 2004
    Inventor: Michael Patane